ONWARD Medical Raises 40.6 Million Euros from Institutional Investors
ONWARD Medical announced on Monday the closure of its private placement with institutional investors. The new shares from this fundraising are now admitted to trading on Euronext Brussels, Amsterdam, and Paris.
The private placement generated a gross product of 40.6 million euros from institutional investors. The newly issued shares are already listed and tradable on the three Euronext exchanges: Brussels, Amsterdam, and Paris, under the ticker ONWD.
About ONWARD Medical
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
ONWARD Medical is a neurotechnology company based in the Netherlands, with a scientific and engineering center in Switzerland and an office in Boston, Massachusetts, USA. The company develops therapies to restore mobility, motor functions, and independence in patients with spinal cord injuries and other movement disorders. It has developed its proprietary ARC Therapy technology and has received ten Breakthrough Device designations from the FDA. Its ARC-EX® system is authorized for marketing in the United States and Europe. ONWARD Medical is also developing an investigational implantable system called ARC-IM®, designed to address unmet medical needs including tension instability after spinal cord injury, and can be combined with a brain-computer interface and artificial intelligence.
SectorDispositifs médicaux et optique›Dispositifs médicaux
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 3,4 millions d'euros
Quarterly revenue: 3,4 millions d'euros
Net income: -24,7 millions d'euros
-81,5 millions d'euros
Risks mentioned
Regulatory approvals delays could impact commercial expansion timelines
Competition and technology changes could affect market positioning
Continued significant operating losses require sustained funding
Opportunities identified
ARC-EX home-use expansion in US Veterans Affairs and additional countries planned for H2 2026
Empower BP global pivotal study advancement with 22 enrolled participants and 14 active clinical sites
Pipeline expansion with planned first clinical feasibility study for bladder function restoration and additional indications exploration
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
